• OS Therapies reported its Phase 2b OST-HER2 study in fully resected pulmonary metastatic osteosarcoma showed a clearer survival benefit versus historical comparisons.
• Updated findings have not yet been presented; detailed results are slated for release at a late-June 2026 osteosarcoma conference.
• The company is adding the updated data to regulatory filings, targeting early market authorizations across major Western markets in 2H 2026.
• Regulators in Europe and Australia have aligned on using upcoming 3-year survival results, expected in early Q4 2026, as a key endpoint.
• A confirmatory Phase 3 trial is expected to start in late Q3 2026 in Australia, a prerequisite for early market access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606020600NEWSFILECNPR____20260602_299769_1) on June 02, 2026, and is solely responsible for the information contained therein.